Invited Presentations
2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992
2024 • Back to top
-
-
- 288. Processing MassTech AP/MALDI Data Using MSiReader v2.8
Russell R. Kibbe, Alena N. Joignant, David C. Muddiman
Breakfast Seminar, 72nd American Society for Mass Spectrometry Conference, Anaheim, CA 2024
2023 • Back to top
-
-
- 287. Prototyping Mass Spectrometry Imaging Instrumentation
Kevan T. Knizner & David C. Muddiman
Workshop, 71st American Society for Mass Spectrometry Conference, Houston, TX 2023
2022 • Back to top
-
-
-
-
-
-
- 286. The Importance of High Resolution Ion Mobility Mass Spectrometry to Accurately Read Back the Complex Language of Biology
David C. Muddiman, Jeffrey Enders, Taufika Williams, & Kenneth P. Garrard
Eastern Analytical Symposium, Plainsboro, NJ 2022 - 285. MSiReader Pro: An Intuitive and Innovative Vender Neutral Software for Mass Spectrometry Imaging
Alena N. Joignant & David C. Muddiman
Pre-Meeting Workshop, IMSS, Baltimore, MD 2022 - 284. From LC-MS and LC-HRIM-MS Glycomics to Mass Spectrometry Imaging: Novel Chemistry and Platform Technologies with Diverse Applications in Human Health and Disease
David C. Muddiman
ACS Fall Conference, Chicago, IL 2022 - 283. Novel 2D and 3D Mass Spectrometry Imaging by IR-MALDESI: From Understanding Cancer and Xenobiotic Metabolism to Wound Healing
David C. Muddiman
Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 2022 - 282. NextGen IR-MALDESI Mass Spectrometry Imaging: Instrument Development and Recent Applications
David C. Muddiman
ACS Spring Conference, San Diego, CA 2022 - 281. Statistical Approach for System Suitability Testing (SST) for Mass Spectrometry Imaging using IR-MALDESI
David C. Muddiman
18th Annual Meeting of the US Human Proteome Organization, Charleston, SC 2022
- 286. The Importance of High Resolution Ion Mobility Mass Spectrometry to Accurately Read Back the Complex Language of Biology
2021 • Back to top
-
-
-
-
- 280. Determination of the Inter-Variability of N-Linked Glycans in Human Frontal Cortex Brain Tissue: From Optimized INLIGHT Chemical Labeling to Ion-Mobility MS
David C. Muddiman
The International Chemical Congress of Pacific Basin Societies 2022 - 279. New Directions in IR-MALDESI Mass Spectrometry Imaging: From Cells, Bones and Neurotransmitters to Drift Tube Ion Mobility
David C. Muddiman
The International Chemical Congress of Pacific Basin Societies 2021 - 278. Quantifying Human Exposure to Emerging Contaminants of Concern using Mass Spectrometry
David C. Muddiman
Isotope Day, Cambridge Isotope Laboratories, Tewsbury, MA 2021 - 277. Scientific Discovery and Impact Through Innovative Mass Spectrometry Measurements: From Plants and Model Organisms to Humans
David C. Muddiman
Department of Chemistry, George Washington University, Washington, DC 2021 - 276. Scientific Discovery and Impact Through Innovative Mass Spectrometry Measurements: From Plants and Model Organisms to Humans
David C. Muddiman
Central Ohio Mass Spectrometry Discussion Group, Columbus, OH 2021 - 275. Scientific Discovery and Impact through Innovative Mass Spectrometry Measurements: From Plants and Model Organisms to Humans
David C. Muddiman
Department of Chemistry and Biochemistry, Auburn University, Auburn, AL 2021
- 280. Determination of the Inter-Variability of N-Linked Glycans in Human Frontal Cortex Brain Tissue: From Optimized INLIGHT Chemical Labeling to Ion-Mobility MS
2020 • Back to top
-
-
-
-
- 274. New Directions for IR-MALDESI Mass Spectrometry Imaging: From Cells and Bones to Drift Tube Ion Mobility
David C. Muddiman and Erin S. Baker
Mass Spectrometry Applications to the Clinical Laboratory, Palm Springs, CA 2020 - 273. New Directions for IR-MALDESI Mass Spectrometry Imaging: From Cells, Bones and Neurotransmitters to Drift Tube Ion Mobility
David C. Muddiman and Erin S. Baker
United States Human Proteome Organization, Seattle, WA 2020 - 272. Scientific Discovery and Impact Through Innovative Mass Spectrometry Measurements: From Plants and Model Organisms to Humans
David C. Muddiman
Thermo Fisher Scientific Global Sales Meeting, San Antonio, TX 2020 - 271. Unraveling Chemical and Biological Systems Through the Development and Application of Innovative Mass Spectrometry Platform Technologies
David C. Muddiman
Department of Marine, Earth and Atmospheric Sciences, NC State University, Raleigh, NC 2020
- 274. New Directions for IR-MALDESI Mass Spectrometry Imaging: From Cells and Bones to Drift Tube Ion Mobility
2019 • Back to top
-
-
-
-
- 270. IR-MALDESI Coupled with Ion Mobility: Early Results
David C. Muddiman
1st Annual North American Ion Mobility User Meeting, Alumni Center, NC State University, Raleigh, NC 2019 - 269. High Throughput Screening by Adaptation of IR-MALDESI-MS
David C. Muddiman
Southeastern Regional Meeting of the American Chemical Society, Savannah, GA 2019 - 268. Infrared Matrix-Assited Laser Desorption Electrospray Ionization (IR-MALDESI): From Fundamentals to New Directions
David C. Muddiman
Agilent Technologies, Santa Clara, CA 2019 - 267. Infrared Matrix-Assisted Laser Desorption Electrospray Ionization (IR-MALDESI) as a Novel Platform for Molecular Microscopy
David C. Muddiman
Asilomar Meeting on Mass Spectrometry, Pacific Grove, CA 2019 - 266. Innovations in Chemistry and Mass Spectrometry Platform Technologies and Their Application to Diverse Biological Problems
David C. Muddiman
Seton Hall University, South Orange, NJ 2019 - 265. Innovations in Chemistry and Mass Spectrometry Platform Technologies and Their Application to Diverse Biological Problems
David C. Muddiman
University of British Columbia, Vancover, Canada 2019 - 264. Innovations in Chemistry and Mass Spectrometry Platform Technologies and Their Application to Diverse Biological Problems
David C. Muddiman
The European Molecular Biology Laboratory, Heidleberg, Germany 2019 - 263. Matrix-Assisted Laser Desorption Electrospray Ionization (MALDESI): Background, Potential, and Limitations
David C. Muddiman
Abbvie Inc, Chicago, IL 2019 - 262. Innovations in Chemistry and Mass Spectrometry Platform Technologies and Their Application to Diverse Biological Problems
David C. Muddiman
Department of Biochemistry, NC State University, Raleigh, NC 2019 - 261. Innovations in Chemistry and Mass Spectrometry Platform Technologies and Their Application to Diverse Biological Problems
David C. Muddiman
Brigham Young University, Provo, UT 2019 - 260. Innovations in Chemistry and Mass Spectrometry Platform Technologies for Quantitative Glycomics
David C. Muddiman, Jaclyn Gowen, James Dodds, Erin S. Baker, Daniel M. Rotroff, James N. Petitte, Alison A. Motsinger-Reif, Michael MacCoss, Thomas Montine
15th Annual Conference of the United States Human Proteome Organization: Proteomics at the Frontier of Biology and Medicine, Rockville, MD 2019
- 270. IR-MALDESI Coupled with Ion Mobility: Early Results
-
-
-
2018 • Back to top
-
-
-
-
- 259. New Advances in IR-MALDESI for Mass Spectrometry Imaging
David C. Muddiman
IMSS II and OurCon VI, Charleston, SC 2018 - 258. Innovations in Chemistry and Mass Spectrometry Platform Technologies for SystemsLevel Measurements
David C. Muddiman
Thermo Fisher Scientific, San Jose, CA 2018 - 257. Innovations in Chemistry and Mass Spectrometry Platform Technologies for
Quantitative Glycomics
David C. Muddiman
Understanding the Role of Glycosylation in Alzheimer’s Disease, Division of
Neuroscience, National Institute on Aging, Bethesda, Maryland 2018 - 256. Innovations in Chemistry and Mass Spectrometry Platform Technologies for SystemsLevel Measurements
David C. Muddiman
Department of Molecular Biomedical Sciences, College of Veterinary Medicine, North
Carolina State University 2018 - 255. Innovations in Mass Spectrometry Platform Technologies to Address Diverse Biological
Research Hypotheses
David C. Muddiman
James Madison University, Harrisonburg, VA 2018 - 254. Development and Application of IR-MALDESI for 2D and 3D Imaging
David C. Muddiman
The Pittsburgh Conference, Orlando, FL 2018 - 253. Development of INLIGHT for Quantiative Glycomics
David C. Muddiman
The Pittsburgh Conference, Orlando, FL 2018 - 252. IR MALDESI: from Technological Innovations to Cancer, HIV Treatment and Exposomics
David C. Muddiman
Mass Spectrometry Applications to the Clinical Laboratory, Palm Springs, CA 2018 - 251. Innovations in Mass Spectrometry Platform Technologies for Epithelial Ovarian Cancer Research and High Throughput Screenings
David C. Muddiman
Washington Chromatography Discussion Group, Rockville, MD 2018
- 259. New Advances in IR-MALDESI for Mass Spectrometry Imaging
-
-
-
2017 • Back to top
-
-
-
-
- 250. IR-MALDESI: An Innovative Approach to Molecular Microscopy
David C. Muddiman
Temple University, Philadelphia, PA 2017 - 249. IR-MALDESI: An Innovative Mass Spectrometry Imaging Platform Technology
David C. Muddiman
SERMACS, Charlotte, NC 2017 - 248. IR-MALDESI: An Innovation Approach to Molecular Microscopy
David C. Muddiman
NIEHS, Research Triangle Park, NC 2017 - 247. Innovative Mass Spectrometry Chemistries and Technologies to Read the Complex Language of Biology
David C. Muddiman
East China Normal University, Shanghai, China 2017 - 246. Innovative Mass Spectrometry Chemistries and Technologies to Read the Complex Language of Biology
David C. Muddiman
Dalian Institute of Chemical Physics, Dalian, China 2017 - 245. Novel Discoveries in Ovarian Cancer and ALS: From Proteome Profiling to Proteoforms
David C. Muddiman
Stockholm University, Stockholm, Sweden in November 2017 - 244. Innovative Mass Spectrometry Approaches to Unravel Biology
David C. Muddiman
Department of Plant and Microbial Biology, NC State University 2017 - 243. Novel Discoveries in Ovarian Cancer and ALS: From Proteome Profiling to Proteoforms
David C. Muddiman
Montreal Mass Spectrometry Discussion Group, Montreal, Canada 2017 - 242. Chemical and Mass Spectrometry Strategies Enabling Human Health Biological Discoveries
David C. Muddiman
Cambridge Isotope Laboratories, Tewksbury, MA 2017 - 241. Elucidation of Novel Proteoforms of Superoxide Dismutase (SOD1) in Sporadic ALS Patients
David C. Muddiman
United States Human Proteome Organization, San Diego, CA 2017 - 240. Novel Discoveries in Ovarian Cancer and ALS: From Proteome Profiling to Proteoforms
David C. Muddiman
OMICS Strategies to Study the Proteome, Breckenridge, CO 2017
- 250. IR-MALDESI: An Innovative Approach to Molecular Microscopy
-
-
-
2016 • Back to top
-
-
-
-
- 239. Elucidation of Novel Proteoforms of Superoxide Dismutase (SOD1) in Sporadic ALS Patients
David C. Muddiman
Thermo Fisher Scientific Seminar Series, Bethesda, MD 2016 - 238. Innovative Chemistries and Technologies to Read the Complex Language of Biology
David C. Muddiman
Washington-Baltimore Mass Spectrometry Discussion Group, Vendor Night, Columbia, MD 2016 - 237. TransOMICS: From Innovative Technology and Model Organisms to Biological Impact
David C. Muddiman
Department of Molecular Science and BioDesign Institute, Arizona State University, Tempe, AZ 2016 - 236. IR-MALDESI Mass Spectrometry Imaging of Complex Chemical and Biological Systems
David C. Muddiman
252nd National American Chemical Society Meeting and Exposition, Philadelphia, PA 2016 - 235. TransOMICS: Integration of IR-MALDESI MSI with LMD Proteomics Data
David C. Muddiman
International Mass Spectrometry Conference, Toronto, Canada 2016 - 234. IR MALDESI: A Novel Molecular Microscopy Method to Determine Drug Distributions in Tissues
David C. Muddiman
Analytica 2016, Munich, Germany 2016 - 233. IR-MALDESI: An Innovative Approach to Molecular Microscopy
David C. Muddiman
Mass Spectrometry Applications to the Clinical Laboratory, Palm Springs, CA 2016 - 232. IR-MALDESI: An Innovation Approach to Molecular Microscopy
David C. Muddiman
Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC 2016
- 239. Elucidation of Novel Proteoforms of Superoxide Dismutase (SOD1) in Sporadic ALS Patients
-
-
-
2015 • Back to top
-
-
-
-
- 231. Working Around the Cluck: A Systems Biology Approach to Understand the Origin and Biology of Ovarian Cancer
David C. Muddiman
Cancer Center, University of Arkansas, Little Rock, AR 2015 - 230. Innovative Molecular Analysis Technologies to Unravel Complex Biological Questions,
David C. Muddiman
Central North Carolina American Chemical Society, Syngenta, Greensboro, NC 2015 - 229. Working Around the Cluck: A Systems Biology Approach to Understand the Origin and Biology of Ovarian Cancer
David C. Muddiman
Department of Biochemistry and Biophysics, University of North Carolina Chapel Hill,
Chapel Hill, NC 2015 - 228. Innovative Molecular Analysis Technologies to Unravel Complex Biological Questions,
David C. Muddiman
Department of Chemistry, Iowa State University, Ames, IA 2015 - 227. Working Around the Cluck: A Systems Biology Approach to Understand the Origin and Biology of Ovarian Cancer
David C. Muddiman
Institute for Systems Biology, Seattle, WA 2015 - 226. Innovative Molecular Analysis Technologies to Unravel Complex Biological Systems
David C. Muddiman
Bay Area Mass Spectrometry Discussion Group, Foster City, CA 2015 - 225. The Importance of Ultrahigh Specificity in Reading the Complex Language of Biology
David C. Muddiman
The Pittsburgh Conference, New Orleans, LA 2015 - 224. The Importance of Ultrahigh Specificity in Reading the Complex Language of Biology
David C. Muddiman
United States Human Proteome Organization, Tempe, AZ 2015
- 231. Working Around the Cluck: A Systems Biology Approach to Understand the Origin and Biology of Ovarian Cancer
-
-
-
2014 • Back to top
-
-
-
-
- 223. Discovery of N-Linked Glycan Biomarkers in Domestic Hen Model of Ovarian Cancer using INLIGHT™ Strategy
David C. Muddiman
6th Annual Meeting of the Proteomics Society, India Institute of Technology, Mumbai, India, 2014 - 222. Quantitative Mass Spectrometry Imaging (QMSI) by a Novel IR-MALDESI Approach
David C. Muddiman
6th Annual Meeting of the Proteomics Society, India Institute of Technology, Mumbai, India, 2014 - 221. Mapping HIV Drug Distributions using a Novel Mass Spectrometry Imaging Source
David C. Muddiman
American Association for Pharmaceutical Sciences, San Diego, CA 2014 - 220. Development of a Novel Atmospheric Pressure Ionization Source for Biological and Chemical Imaging
David C. Muddiman
SERMACS, Nashville, TN 2014 - 219. Quantitatively Controlling Chaos: The N-Linked Glycome of an Integrated Systems Biology Approach to Understanding Ovarian Cancer Initiation and Progression
David C. Muddiman
Asilomar Conference, Advances in Glycomics and Glycoproteomics: Methods and Applications, Pacific Grove, CA 2014 - 218. Matrix-Assisted Laser Desorption Electrospray Ionization (MALDESI): From Fundamentals to Tissue and Chemical Imaging
David C. Muddiman
248th ACS National Meeting, San Francisco, CA 2014 - 217. Quantitatively Controlling Chaos: Adventures in Absolute Protein Quantification
David C. Muddiman
Cold Spring Harbor Laboratory, Long Island, NY 2014 - 216. Thing 1 and Thing 2 (and Thing 3): ESI, MALDI and Hybrids of the Two
David C. Muddiman
Cold Spring Harbor Laboratory, Long Island, NY 2014 - 215. Mapping HIV Drugs in Tissue using IR-MALDESI MSI Coupled to the Q-Exactive with Several Acquisition Modes
David C. Muddiman, Jeremy A. Barry, Guillaume Robichaud, Mark Bokhart, Elias Rosen, Milad Nazari, Troy Ghashghaei, Corbin Thompson, Craig Sykes, and Angela Kashuba
62nd ASMS Conference on Mass Spectrometry and Allied Topics, Baltimore, MD 2014 - 214. Development of the INLIGHT™ Strategy for the Relative Quantification of N-Linked Glycans using Different Separation Modes
David C. Muddiman, Amber C. Cook, James P. McCord, Liangliang Sun, Norman J. Dovichi
HPLC 2014, New Orleans, LA 2014 - 213. Quantitatively Controlling Chaos: The New Biology
David C. Muddiman
Triangle Area Mass Spectrometry Discussion Group, Genome Sciences, UNC Chapel Hill 2014 - 212. Infrared MALDESI Imaging Source Coupled to Q-Exactive for Discovery-Based and Targeted Analysis of Endogenous and Exogenous Species in Tissues
David C. Muddiman
Frontiers in Instrumentation, 10th Annual United States Human Proteome Organization, Seattle, WA 2014 - 211. Quantitative and Comprehensive Chemistry and Technology: THE NEW BIOLOGY
David C. Muddiman
Arizona Mass Spectrometry Discussion Group, Tucson, AZ 2014 - 210. Development of the INLIGHT™ Strategy for the Relative Quantification of N-Linked Glycans in Complex Biospecimens
David C. Muddiman
The Pittsburgh Conference, Chicago, IL 2014 - 209. Quantitative and Comprehensive Chemistry and Technology: THE NEW BIOLOGY
David C. Muddiman
Eastern Virginia Medical School, Norfolk, VA 2014 - 208. Innovative Chemical and Instrumental Approaches Directed at Unraveling Complex Biological Systems
David C. Muddiman
Department of Chemistry and Biochemistry, University of North Carolina at Greensboro, Greensboro, NC 2014 - 207. Innovative Chemical and Instrumental Approaches Directed at Unraveling Complex Biological Systems
David C. Muddiman
Department of Chemistry, University of Alberta, Edmonton, AL 2014
- 223. Discovery of N-Linked Glycan Biomarkers in Domestic Hen Model of Ovarian Cancer using INLIGHT™ Strategy
-
-
-
2013 • Back to top
-
-
-
-
- 206. Development of Novel Chemical and Instrumental Methods using Design of Experiments for Quantitative Proteomic, Glycomic, Metabolomic, and Lipidomic Measurements in Complex Biological Systems
David C. Muddiman
Department of Chemistry and Chemical Biology, Northeastern University, Boston, MA 2013 - 205. Development and Application of the INLIGHT Relative Quantification Strategy: From Monitoring Glycostasis to Early Detection of Ovarian Cancer
David C. Muddiman
Boston Glycobiology Discussion Group, Boston University Medical Campus, Boston, MA 2013 - 204. Fundamentals and Applications of Infrared Matrix-Assisted Laser Desorption Electrospray Ionization Source for Mass Spectrometry Imaging
David C. Muddiman
246th ACS National Meeting, Indianapolis, IN 2013 - 203. Individuality Normalization and Labeling with Isotopic Glycan Hydrazide Tags (INLIGHT): A Novel Glycan Relative Quantification Strategy, Development and Application
David C. Muddiman, S. Hunter Walker, Amber C. Cook, Amber D. Taylor
Cold Spring Harbor Laboratory, Long Island, NY 2013 - 202. Mass Spectrometry-Based Absolute Protein Quantification
David C. Muddiman and Philip L. Loziuk
Cold Spring Harbor Laboratory, Long Island, NY 2013 - 201. Electrospray Ionization, Matrix-Assisted Laser Desorption Ionization, and Hybrid of the Two: From Mechanisms to Imaging
David C. Muddiman, Jeremy A. Barry, and Guillaume Robichaud
Cold Spring Harbor Laboratory, Long Island, NY 2013 - 200. Proteolysis and Peptide Decay: Considerations for Discovery and Targeted Proteomic Workflows with Applications to Systems Modeling of Lignin and Cellulose Biosynthesis
David C. Muddiman and Philip L. Loziuk
American Society for Mass Spectrometry, Minneapolis, MN 2013 - 199. Innovations and Findings in Academic Research: Translating them to the Pharmaceutical Industry
David C. Muddiman
GlaxoSmithKline, Worldwide VTC, RTP, NC 2013
- 206. Development of Novel Chemical and Instrumental Methods using Design of Experiments for Quantitative Proteomic, Glycomic, Metabolomic, and Lipidomic Measurements in Complex Biological Systems
-
-
-
2012 • Back to top
-
-
-
-
- 198. N-Linked Glycan Hydrophobic Tagging, Profiling, and Relative Quantification Strategy Toward Biomarker Discovery Efforts in the Hen Model of Spontaneous Ovarian Cancer
David C. Muddiman
National Institutes of Health, Innovative Molecular Analysis Technologies Meeting, Houston, TX 2012 - 197. Chemical and Synthetic Biology Approaches for Polyketide Diversification
G. Williams, J. McArthus, S. Randall, M. Draelos, E.M. Musiol, Z. Ye, C. Ladner, D.C. Muddiman, T. Weber
Southeastern Regional Meeting of the American Chemical Society, Raleigh, NC 2012 - 196. Ambient Tissue Imaging using Infrared Matrix-Assisted Laser Desorption Electrospray Ionization Mass Spectrometry
David C. Muddiman
Southeastern Regional Meeting of the American Chemical Society, Raleigh, NC 2012 - 195. New Chemical and Instrumental Tools for Quantitatively Exploring the N-Linked Glycome
David C. Muddiman
Boston Glycobiology Discussion Group, Boston, MA 2012 - 194. Development of Novel Chemical and Instrumental Methods using Design of Experiments for Quantitative Proteomic Measurements in Complex Biological Systems
David C. Muddiman
Department of Chemistry, Brandeis University, Boston, MA 2012 - 193. N-linked Glycan Profiling Strategy Toward Biomarker Discovery Efforts in the Hen Model of Spontaneous Ovarian Cancer
David C. Muddiman and S. Hunter Walker
4th Charles Warren Workshop, CCRC, University of Georgia, Athens, GA 2012 - 192. MALDI, ESI and Hybrids of the Two
David C. Muddiman, Jeremy A. Barry, and Guillaume Robichaud
Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 2012 - 191. Mass Spectrometry-based Absolute Protein Quantification
David C. Muddiman and Christopher M. Shuford
Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 2012 - 190. The Impact of Fourier Transform Mass Spectrometry on Biological Research
David C. Muddiman
The Pittsburgh Conference, Orlando, FL 2012 (Award Symposium Honoring Alan Marshall) - 189. Proteomics and Glycomics Tools for the Study of Human Disease
David C. Muddiman
GlaxoSmithKline, King of Prussia, PA 2012 - 188. N-Linked Glycan Hydrophobic Tagging, Profiling, and Relative Quantification Strategy Toward Biomarker Discovery Efforts in the Hen Model of Spontaneous Ovarian Cancer
David C. Muddiman
National Institutes of Health, Innovative Molecular Analysis Technologies Meeting, Houston, TX 2012 - 187. Chemical and Synthetic Biology Approaches for Polyketide Diversification
G. Williams, J. McArthus, S. Randall, M. Draelos, E.M. Musiol, Z. Ye, C. Ladner, D.C. Muddiman, T. Weber
Southeastern Regional Meeting of the American Chemical Society, Raleigh, NC 2012 - 186. Ambient Tissue Imaging using Infrared Matrix-Assisted Laser Desorption Electrospray Ionization Mass Spectrometry
David C. Muddiman
Southeastern Regional Meeting of the American Chemical Society, Raleigh, NC 2012 - 185. New Chemical and Instrumental Tools for Quantitatively Exploring the N-Linked Glycome
David C. Muddiman
Boston Glycobiology Discussion Group, Boston, MA 2012 - 184. Development of Novel Chemical and Instrumental Methods using Design of Experiments for Quantitative Proteomic Measurements in Complex Biological Systems
David C. Muddiman
Department of Chemistry, Brandeis University, Boston, MA 2012 - 183. N-linked Glycan Profiling Strategy Toward Biomarker Discovery Efforts in the Hen Model of Spontaneous Ovarian Cancer
David C. Muddiman and S. Hunter Walker
4th Charles Warren Workshop, CCRC, University of Georgia, Athens, GA 2012 - 182. MALDI, ESI and Hybrids of the Two
David C. Muddiman, Jeremy A. Barry, and Guillaume Robichaud
Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 2012 - 181. Mass Spectrometry-based Absolute Protein Quantification
David C. Muddiman and Christopher M. Shuford
Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 2012 - 180. The Impact of Fourier Transform Mass Spectrometry on Biological Research
David C. Muddiman
The Pittsburgh Conference, Orlando, FL 2012 (Award Symposium Honoring Alan Marshall) - 179. Proteomics and Glycomics Tools for the Study of Human Disease
David C. Muddiman
GlaxoSmithKline, King of Prussia, PA 2012
- 198. N-Linked Glycan Hydrophobic Tagging, Profiling, and Relative Quantification Strategy Toward Biomarker Discovery Efforts in the Hen Model of Spontaneous Ovarian Cancer
-
-
-
2011 • Back to top
-
-
-
-
- 178. Novel Reagents to Probe the N-Linked Glycome for the Study of Spontaneous EOC in the Chicken Model
David C. Muddiman
Innovative Molecular Analysis Technologies, National Cancer Institute, Bethesda, MD 2011 - 177. New Chemical and Instrumental Tools for Exploring the Proteome and Glycome
David C. Muddiman
Department of Chemistry, Brown University, Providence, RI 2011 - 176. From Innovative Technologies to Model Organisms: The Search for Biomarkers for the Detection of Early Stage Epithelial Ovarian Cancer
David C. Muddiman
UW- Madison Human Proteomics Symposium, Madison, WI 2011 - 175. Characterization of the UV- and IR-Matrix-Assisted Laser Desorption Ionization (MALDESI) Source with Integrated RASTIR
MARM of the American Chemical Society, College Park, MD 2011 - 174. Innovative Approaches to Proteomics and Glycomics Research
David C. Muddiman
Department of Chemistry and Biochemistry, The Ohio State University, Columbus, OH 2011 - 173. Intra- and Inter-Individual Variability of Plasma Proteins in the Chicken Model of Spontaneous Epithelial Ovarian Cancer via Selected Reaction Monitoring
Adam Hawkridge; Genna Andrews; James Petitte; David C. Muddiman
7th Annual United State Human Proteome Organization Meeting, Raleigh, NC 2011 - 172. Innovative Approaches to Proteomics and Glycomics Research
David C. Muddiman
Department of Chemistry and Biochemistry, University of North Carolina-Greensboro, North Carolina 2011 - 171. Innovation and Application of Proteomics and Glycomics Strategies Directed at Epithelial Ovarian Cancer
David C. Muddiman
The Scripps Research Institute, Jupiter, Florida, 2011
- 178. Novel Reagents to Probe the N-Linked Glycome for the Study of Spontaneous EOC in the Chicken Model
-
-
-
2010 • Back to top
-
-
-
-
- 170. Development of Novel Strategies for Proteomics and Glycomics Research
David C. Muddiman
Eastern Analytical Symposium Honoring Richard D. Smith, 2010 EAS Awardee for Outstanding Achievements in the Fields of Analytical Chemistry, East Somerset, New Jersey,
2010 - 169. Matrix-Assisted Laser Desorption Electrospray Ionization: Mechanisms, Technology, and Application
David C. Muddiman
26th Asilomar Conference on Mass Spectrometry, Pacific Grove, CA, 2010 - 168. Development and Application of Mass Spectrometry-Based Biomarker Discovery Technologies for the Early Detection of Epithelial Ovarian Cancer
David C. Muddiman
The University of Texas Health Science Center at San Antonio, San Antonio, TX, 2010 - 167. Development and Application of Mass Spectrometry-Based Biomarker Discovery Technologies for the Early Detection of Epithelial Ovarian Cancer
David C. Muddiman
Texas A&M; University, College Station, TX, 2010 - 166. Matrix-Assisted Laser Desorption Electrospray Ionization (MALDESI)
David C. Muddiman
Precision Engineering Center, Monteith Engineering Research Center, North Carolina State University, Raleigh, NC, 2010 - 165. New Ionization Methods for Large-Molecule Top-Down Mass Spectrometry
David C. Muddiman
United States Human Proteome Organization, Denver, CO, 2010 - 164. Proteomics and Glycomics Approaches to Elucidate Biomarkers for the Early Detection of Ovarian Cancer
David C. Muddiman
PittCon 2010, Orlando, Florida, 2010
- 170. Development of Novel Strategies for Proteomics and Glycomics Research
-
-
-
2009 • Back to top
-
-
-
-
- 163. Development and Application of Chemical and Instrumental Approaches Directed at Biomarker Discovery
David C. Muddiman
Department of Chemistry, Louisiana State University, Baton Rouge, LA, 2009 - 162. Development and Application of Chemical and Instrumental Approaches Directed at Biomarker Discovery
David C. Muddiman
Department of Chemistry, George Washington University, Washington, DC, 2009 - 161. Developing Novel Hybrid Ionization Sources Around the MALDESI Technology Platform
Adam M. Hawkridge and David C. Muddiman
Federation of Analytical Chemistry and Spectroscopy Societies, Louisville, KY, 2009 - 160. Mass Spectrometry-Based Biomarker Discovery: Towards a Global Proteome Index-of-Individuality
David C. Muddiman and Adam M. Hawkridge
Pharmaceutical and Biomedical Analysis, Orlando, FL, 2009 - 159. The Development of an Aerodynamic Focusing Device, the Air Amplifier, for Improved Biomarker Analyses by Mass Spectrometry
David C. Muddiman, R. Brent Dixon, Amarnatha S. Potturi, Dan Cassidy, Jack R. Edwards, Alex Sohn, Guillaume Robichaud, Thomas A. Dow
NCI IMAT Grantee Meeting, Bethesda, MD, 2009 - 158. Rationale Ovarian Cancer Biomarker Discovery: The Importance of Longitudinal Experimental Designs
David C. Muddiman
ADAPT Congress, Washington, DC, 2009 - 157. Cancer Biomarker Discovery and Quantification using Mass Spectrometry
David C. Muddiman
Precision Engineering Center, Monteith Engineering Research Center, North Carolina State University, Raleigh, NC, 2009 - 156. Development and Application of Chemical and Instrumental Approaches Directed at Biomarker Discovery
David C. Muddiman
Department of Chemical and Biomolecular Engineering, North Carolina State University, Raleigh, NC, 2009 - 155. Ambient Ionization Methods Coupled to FTMS for Direct Analysis and Imaging Applications
David C. Muddiman
Center for Analytical and Instrumentation Development, Purdue University, West Lafayette, IN, 2009 - 154. Development of Atmospheric Pressure Ionization Sources Coupled to FT-ICR Mass Spectrometry for the Characterization of Biological Molecules
David C. Muddiman, Jason S. Sampson, K.K. Murray, R.B. Dixon
7th North American FT MS Conference, Key West, FL, 2009 - 153. Development and Application of FT-ICR Mass Spectrometry for Proteomics and Glycomics Research
BASF, The Chemical Company, Research Triangle Park, NC, 2009 - 152. Aligning Chemistry and High End Mass Spectrometry with Important Clinical Problems: Building a Strong Foundation Based on Interdisciplinary Collaborations
David C. Muddiman
Department of Chemistry, UNC Chapel Hill, Chapel Hill, NC, 2009 - 151. Integration of Engineering, Chemistry, and Medicine: Progress Towards the Molecular Characterization of Cancer
David C. Muddiman
Department of Chemistry, NC A & T University, Greensboro, NC, 2009
- 163. Development and Application of Chemical and Instrumental Approaches Directed at Biomarker Discovery
-
-
-
2008 • Back to top
-
-
-
-
- 150. Innovative Ionization Sources for Imaging Mass Spectrometry
David C. Muddiman
Department of Chemistry, Georgia Institute of Technology, Atlanta, GA, 2008 - 149. A Combinatorial Approach: The Use of MALDI-MS and Nano LC-MS for Glycan Biomarker Discovery
David C. Muddiman
Diosynth Biotechnology, Cary, NC, 2008 - 148. New Ionization Sources for Biological Mass Spectrometry
David C. Muddiman
Asilomar Conference on Mass Spectrometry, New Methods, Instrumentation, and Applications of Ion Traps, Pacific Grove, CA, 2008 - 147. Time-of-Flight Mass Analyzers: Single-Ion Counting versus ADC Detection
David C. Muddiman
US LC/MS Innovations Seminar Tour, Agilent Technologies, Durham, NC, 2008 - 146. Innovative Technology Development Directed at the Elucidation of Biomarkers for the Detection of Early-State Ovarian Cancer
Taufika I. Williams, Michael S. Bereman, D. Keith Williams, Kimberly K. Kalli, William A. Cliby and David C. Muddiman
National Cancer Institute, Innovative Molecular Analysis Technologies, Cambridge, MA, 2008 - 145. A Combinatorial Approach: The Use of MALDI-MS and Nano LC-MS for Glycan Biomarker Discovery
Taufika Islam Williams, Michael S. Bereman, Kimberly A. Kalli, William A. Cliby and David C. Muddiman
Sixth Annual Protein Biomarkers Conference, Philadelphia, PA, 2008 - 144. Driving Research with a Multidisciplinary Approach
David C. Muddiman
Bioinformatics and Bioengineering Summer Institute, Virginia Commonwealth University, Richmond, VA, 2008 - 143. Glycan Profiling in Plasma: Fundamentals and Applications to Ovarian Cancer
Taufika Islam Williams and David C. Muddiman
The Pittsburgh Conference, New Orleans, LA, 2008
- 150. Innovative Ionization Sources for Imaging Mass Spectrometry
-
-
-
2007 • Back to top
-
-
-
-
- 142. Mass Spectrometry Detection Techniques Available for Qualitative and Quantitative Assays – Small vs. Large Molecules
David C. Muddiman
American Association of Pharmaceutical Scientists, San Diego, CA, 2007 - 141. Fundamentals and Applications of DESI and MALDESI Coupled to FT-ICR-MS
David C. Muddiman
Workshop on The Art of Open Air Ionization on Surfaces, Philadelphia, PA, November 8-9, 2007 - 140. Plasma Biomarker Discovery and Analysis using FT-ICR Mass Spectrometry
David C. Muddiman, Adam Hawkridge, Taufika I. Williams, William Cliby, and John Burnett
Federation of Analytical Chemistry and Spectroscopy Societies Memphis, TN, 2007 - 139. Development of Hybrid Atmospheric Ionization Sources for Direct Analysis of Macromolecules by FT-ICR-MS
David C. Muddiman, Adam Hawkridge, Jason S. Sampson, Michael S. Bereman and R. Brent Dixon
Federation of Analytical Chemistry and Spectroscopy Societies Memphis, TN, 2007 - 138. New Mass Spectrometric Proteomic Technologies
David C. Muddiman
Metabolomics and Proteomics Seminar Series, Department of Biochemistry, University of Minnesota, St. Paul, MN, 2007 - 137. Advancing Quantitative Proteomics Technologies
David C. Muddiman
Minnesota Mass Spectrometry Discussion Group, Minneapolis, MN, 2007 - 136. Chemical and Mass Spectrometry Advances for Improved Clinical Proteomic Measurements David C. Muddiman
Department of Chemistry, University of Michigan, Ann Arbor, MI, 2007 - 135. nanoRP-HPLC and SCX-nanoRP-HPLC coupled to FT-ICR Mass Spectrometry to Effectively Address Complex Biological Mixtures
David C. Muddiman
Triangle Chromatography Discussion Group Symposium, Raleigh, NC, 2007 - 134. Statistical Issues in Mass Spectrometry Based Proteomics
David C. Muddiman
Department of Statistics, North Carolina State University, Raleigh, NC, 2007 - 133. Innovations and Applications of the LTQ-FT in the Biological Arena
David C. Muddiman
ThermoElectron Users Meeting, Cincinnati, OH, 2007 - 132. Innovations and Applications of the LTQ-FT in the Biological Arena
David C. Muddiman
ThermoElectron Users Meeting, Chicago, IL, 2007 - 131. Novel Chemical and Instrumental Approaches to Effectively Address Clinical Proteomic Problems
David C. Muddiman
Department of Chemistry, Vanderbilt University, Nashville, TN, 2007 - 130. Innovations in Ion Sources for Biological FT-ICR Mass Spectrometry
David C. Muddiman
6th North American FT-ICR MS Conference, Lake Tahoe, CA, 2007 - 129. Innovations and Applications of the LTQ-FT in the Biological Arena
David C. Muddiman
ThermoElectron Users Meeting, Lake Tahoe, CA, 2007 - 128. Effectively Addressing Clinical Proteomic Problems using Novel Chemical and Instrumental Approaches
David C. Muddiman
Department of Pharmaceutics, Virginia Commonwealth University, Richmond, VA, 2007
- 142. Mass Spectrometry Detection Techniques Available for Qualitative and Quantitative Assays – Small vs. Large Molecules
-
-
-
2006 • Back to top
-
-
-
-
- 127. Traps, TOF’s and Triples Applied to Global and Targeted Clinical Proteomics
David C. Muddiman
Divisions of Molecular Pharmaceutics and Medicinal Chemistry, University of North Carolina-Chapel Hill, Chapel Hill, NC, 2006 - 126. Selective Chemistry and Advancing Mass Spectrometry Instrumentation to Effectively Approach Challenging Clinical Questions
David C. Muddiman and Adam M. Hawkridge
Department of Chemistry, Georgia Institute of Technology, Atlanta, GA, 2006 - 125. Novel Chemical and Instrumental Approaches Coupled to ESI-FT-ICR Mass Spectrometry to Effectively Address Proteomics Questions
David C. Muddiman
Department of Genome Sciences, University of Washington, Seattle, WA, 2006 - 124. Development of nLC-dualESI-FT-ICR MS and it Applications in Cancer and Cardiovascular Plasma Proteomics
David C. Muddiman and Adam M. Hawkridge
Federation of Analytical Chemistry and Spectroscopy Societies Lake Buena Vista, FL, 2006 - 123. A Primer and Update on the Current State of Large Molecule Quantification
David C. Muddiman
Applied Pharmaceutical Analysis, The Boston Society for Advanced Therapeutics, Boston, MA, 2006 - 122. FT-ICR Mass Spectrometry: Putting a High Resolving Power Spin on Protein Identification and Quantification
David C. Muddiman, Adam H. Hawkridge, Kenneth L. Johnson, and H. Robert Bergen III
231st National American Chemical Society Meeting, Symposium Honoring Richard Caprioli, Recipient of the 2006 Field and Franklin Award, Atlanta, GA, 2006
- 127. Traps, TOF’s and Triples Applied to Global and Targeted Clinical Proteomics
-
-
-
2005 • Back to top
-
-
-
-
- 121. Putting a High Resolving Power Spin on Proteomics in the Clinical Domain
David C. Muddiman
ThermoElectron Proteomics Series, Atlanta, GA, 2005 - 120. Fourier Transform Ion Cyclotron Resonance Mass Spectrometry: Putting a High Resolving Power Spin on Macromolecular Ions
David C. Muddiman
Department of Chemistry, East Carolina University, Greenville, NC, 2005 - 119. Putting a High Resolving Power Spin on Proteomics in the Clinical Domain
David C. Muddiman
ThermoElectron Proteomics Series, Rochester, NY, 2005 - 118. Protein Biomarker Discovery: A Tale of Technologies on a Journey Worth Making
David C. Muddiman
Department of Chemistry and Biochemistry, University of Maryland, College Park, MD, 2005 - 117. Protein Biomarker Discovery in Plasma Based on FT-ICR Mass Spectrometry
David C. Muddiman
Department of Chemistry, University of Georgia, Athens, GA, 2005 - 116. Ovarian Cancer Biomarker Discovery: A Tale of Technologies
David C. Muddiman
AACR/NCI/EORTC International Conference” Molecular Targets and Cancer Therapeutics: Discovery, Biology and Clinical Applications, Philadelphia, PA, 2005 - 115. Aligning High-End Mass Spectrometry with the Clinical Laboratory: Baby Steps on a Journey Worth Making
David C. Muddiman
Mass Spectrometry in the Clinical Lab: Matching Technology to Application, American Association for Clinical Chemistry, Orlando, FL, 2005 - 114. Identification and Relative and Absolute Quantification of Proteins using FT-ICR Mass Spectrometry
David C. Muddiman
Korean Research Institute of Standards and Technology, Taejon, Korea, 2005 - 113. Traps, Triples and TOF’s in the Clinical Domain: Proteomics in the Medical Field
David C. Muddiman
Seoul University National Hospital, Seoul, Korea, 2005 - 112. Traps, Triples and TOF’s in the Clinical Domain: Proteomics in the Medical Field
David C. Muddiman
Inje University Sanggye Paik Hospital, Seoul, Korea, 2005 - 111. Implementation of nanoLC-FT-ICR Mass Spectrometry for Studying Circulating Forms of Brain Natriuretic Peptide in Congestive Heart Failure Patients
Adam M. Hawkridge, Denise M. Heublein, H. Robert Bergen III, John C. Burnett, Jr., David C. Muddiman
North American ICR Meeting, Key West, Florida, 2005 - 110. The Utility of FT-ICR Mass Spectrometry in the Clinical Domain: From Discovery to Targeted Proteomics
David C. Muddiman
Trapped Ion Meeting, Oxford University, London, England, 2005 - 109. Accurate Characterization of Nucleic Acids by FT-ICR Mass Spectrometry, LGC, Southwestern, England, 2005
- 108. Unraveling the Low Molecular Weight Serum and Plasma Proteome using LC- FT-ICR MS: The Search for Biomarkers Predictive for Early Stage Ovarian and Pancreatic Cancer
David C. Muddiman, Adam H. Hawkridge, Kenneth L. Johnson, Ann L. Oberg, Christopher J. Mason, H. Robert Bergen III, William A. Cliby, Janet E. Olson
The Association of Biomolecular Resource Facilities, Savannah, GA, 2005 - 107. Development of a Robust Biomarker Discovery Platform Based on LC-FT-ICR Mass Spectrometry
David C. Muddiman
Department of Chemistry, University of Massachusetts-Amherst, 2005 - 106. Protein Marker Discovery in Plasma and Serum: At the Bleeding Edge of Measurement Science
David C. Muddiman
Department of Chemistry, Oregon State University, Corvallis, Oregon, 2005 - 105. Clinical Proteomics: Making an Impact through the Chemistry Porthole and Building Diverse Research Teams
David C. Muddiman
Department of Chemistry, Carleton College, Northfield, Minnesota, 2005
- 121. Putting a High Resolving Power Spin on Proteomics in the Clinical Domain
-
-
-
2004 • Back to top
-
-
-
-
- 104. The Challenges and Opportunities of Bringing Proteomics into the Clinical Laboratory
David C. Muddiman
Endocrine Research Group, St. Mary’s Hospital, Rochester, MN, 2004 - 103. Proteomic Measurements based on FT-ICR Mass Spectrometry: Challenges and Opportunities
David C. Muddiman
Proteome Society Meeting, London, Ontario, 2004 - 102. Clinical Proteomics: At the Bleeding Edge of Measurement Science
David C. Muddiman
University of Western Ontario, London, Ontario, 2004 - 101. Mass Spectrometry Based Proteomics: From Discovery to Translation
David C. Muddiman
Lillehei Heart Institute, University of Minnesota, Minneapolis, MN, 2004 - 100. Targeted and Biomarker Discovery Proteomics using 1D and 2D LC FT-ICR Mass Spectrometry
David C. Muddiman
3M Corporation, Saint Paul, MN, 2004 - 99. The Role and Impact of 1 and 2D-LC FT-ICR Mass Spectrometry in the Clinical Arena: From Fundamentals to Applications
David C. Muddiman
Philip Morris, Richmond Virginia, 2004 - 98. Biomarker Discovery in Plasma and Serum: Establishment of a Powerful Platform based on High-Field Magnets
David C. Muddiman
Manfred W. Comfort Symposium, Radisson Hotel, Rochester, MN, 2004 - 97. Translation of Proteomic Discoveries from the Basic Science to the Clinical Laboratory: The Challenges and Opportunities
David C. Muddiman
Keynote Speaker, American Motility Society Annual Meeting, 2004 - 96. Biomarker Discovery using a nanoLC-dualESI FT-ICR Mass Spectrometry Platform
D.C. Muddiman
Protein Biomarkers 2004, Philadelphia, PA, 2004 - 95. An Integrated Biomarker Discovery Platform Based on nanoLC-dual-ESI-FT-ICR Mass Spectrometry
A.M. Hawkridge, C.J. Mason, K.L. Johnson, H.R. Bergen, and D.C. Muddiman
31st Annual Federation of Analytical Chemistry and Spectroscopy Societies Meeting, Portland, OR, 2004 - 94. Shining a High Resolving Power Spin on Biological Macromolecules
D.C. Muddiman
Arthur F. Findeis Award Lecture, American Chemical Society, Philadelphia, PA, 2004 - 93. Detection of TTR Variants and Evaluation of siRNA in Mice as a Potential Therapy for Familial Amyloidosis
D.C. Muddiman
Amyloid Research Group, Mayo Clinic College of Medicine, Rochester, MN, 2004 - 92. The Role of Modern Mass Spectrometry in 21st Century: Fundamental Developments and Emerging Applications
D.C. Muddiman
Young Mass Spectrometrists, American Society for Mass Spectrometry, Nashville, TN, 2004 - 91. The Classical ER Transcriptional Pathway
T .C. Spelsberg, D.G. Monroe, F.J. Secreto, D.C. Muddiman, B.L. Riggs, S. Khosla
American Society for Bone and Mineral Research, Bethesda, Maryland, 2004 - 90. Biomarker Discovery using High Performance Mass Spectrometry
David C. Muddiman
Cambridge Healthtech Institute’s Protein Biomarkers: HighEnd Mass Spectrometry, Philadelphia, PA, 2004. - 89. The Challenges and Opportunities of Doing Proteomics in a Single Cell
David C. Muddiman
Cambridge Healthtech Institute’s Eighth Annual Proteomics Meeting. Proteomics: Addressing Challenges in Proteomic Analysis, San Francisco, CA, 2004 - 88. Comprehensive Proteomics: The Integration of High Performance Mass Spectrometry, Genomics and Bioinformatics to Improve Our Understanding of Disease
David C. Muddiman
J. Craig Venter Science Foundation Joint Technology Center, Rockville, MD, 2004 - 87. Global and Targeted Proteomics using High Performance Mass Spectrometry
David C. Muddiman
Symposium on Genomic and Proteomic Approaches Toward the Understanding of Drug Addiction, Basic Research Center on Molecular and Cell Biology of Drug Abuse (MCBDA) at the University of Minnesota, Minneapolis, MN, 2004 - 86. Proteomics at the Clinical Interface
David C. Muddiman
95th Annual Meeting of the Society of Neurological Surgeons, New Orleans, LA, 2004 - 85. High Field LC-ESI FT-ICR Mass Spectrometry: From Gas-Phase Ion Chemistry to Clinical Applications
David C. Muddiman
Southern Illinois University, Carbondale, IL, 2004 - 84. Biomarker Discovery: High Performance Mass Spectrometry
David C. Muddiman and Janet E. Olson
Pancreatic Cancer Annual SPORE Retreat, Mayo Clinic College of Medicine, Rochester, MN, 2004 - 83. Protein Characterization in Biological Fluids using High Performance Mass Spectrometry
David C. Muddiman
St. Olaf College, Northfield, MN, 2004 - 82. Nucleic Acid Analysis Using High Field FT-ICR Mass Spectrometry
David C. Muddiman
Keystone Symposium on Mass Spectrometry in Systems Biology, Santa Fe, NM, 2004 - 81. Clinical Proteomics by Multidimensional Chromatography Coupled with ESI FT-ICR Mass Spectrometry
David C. Muddiman
The Pittsburgh Conference (Pittcon 2004), Chicago, IL, 2004 - 80. Development of High Performance Mass Spectrometry to Address Complex Biological Problems
David C. Muddiman
University of St. Thomas, Minneapolis, MN, 2004 - 79. LC-ESI-FT-ICR Mass Spectrometry: The Ultimate in Peak Capacity and Adaptability for Measuring Biological Molecules
David C. Muddiman
Department of Chemistry, University of Minnesota, Minneapolis, MN, 2004 - 78. Unraveling Biological Complexity with High Performance Mass Spectrometry
David C. Muddiman
Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, 2004
- 104. The Challenges and Opportunities of Bringing Proteomics into the Clinical Laboratory
-
-
-
2003 • Back to top
-
-
-
-
- 77. MS-Based Proteomics: Instrumentation and Clinical Applications
David C. Muddiman
Resident Lecture Series, Mayo Clinic College of Medicine, 2003 - 76. Ovarian Cancer Biomarker Discovery using 1D and 2D LC-High Performance Mass Spectrometry
David C. Muddiman
Ovarian Cancer Research and Clinical Team, Mayo Clinic College of Medicine, 2003 - 75. Targeted and Discovery Proteomics using High Performance Mass Spectrometry
David C. Muddiman
Clinical Biochemistry and Immunology, Mayo Clinic College of Medicine, 2003 - 74. Clinical Proteomic Applications of LC-ESI-FT-ICR Mass Spectrometry
David C. Muddiman
Associated Regional and University Pathologists, Salt Lake City, Utah, 2003 - 73. Fundamentals and Biological Applications of ESI-FT-ICR Mass Spectrometry
David C. Muddiman
Brigham Young University, Provo, Utah, 2003 - 72. Multidimensional Chromatography ESI-FT-ICR Mass Spectrometry: The Ultimate Peak Capacity for Proteome Measurements
David C. Muddiman
The 35th Central Regional Meeting of the American Chemical Society, Pittsburgh, PA, 2003 - 71. Beyond Genomics: The Promise of Proteomics
David C. Muddiman
Genomics in Clinical Practice, Genetic Testing: Past, Present and Future, Mayo School of Continuing Medical Education, Rochester, MN, 2003 - 70. Comprehensive and Rational Ovarian Cancer Biomarker Discovery using High Performance Mass Spectrometry-Based Proteomics
David C. Muddiman
Women’s Cancer 2003: Merging Science and Care, Mayo Clinic Cancer Center, Rochester, MN, 2003 - 69. Targeted and Global Proteomics by 1D and 2D LC-FT-ICR Mass Spectrometry
David C. Muddiman
American Society for Bone and Mineral Research Annual Meeting, Minneapolis, MN, 2003 - 68. Clinical Proteomics using One and Two-Dimensional LC Coupled with High Field FT-ICR Mass Spectrometry
David C. Muddiman
Seminar at Medical College of Wisconsin, Milwaukee, WI, 2003 - 67. Proteomics FT-ICR Style: A Tribute to John Fenn’s Invention
David C. Muddiman
Mary E. Kapp Lecturer, Virginia Commonwealth University, Richmond, VA, 2003 - 66. Electrospray Ionization Mass Spectrometry of Proteins
David C. Muddiman
Research Workshop, Wisconsin Symposium III, DNA Conference, Visiting Faculty Member, University of Wisconsin-Madison Medical School, Madison, WI, 2003 - 65. Electrospray Ionization Mass Spectrometry of Nucleic Acids: From DNA: Drug Binding to Genotyping
David C. Muddiman
Wisconsin Symposium III, DNA Conference, Visiting Faculty Member, University of Wisconsin-Madison Medical School, Madison, WI, 2003 - 64. Comprehensive Proteomics in a Single Cell: Technology and Applications
David C. Muddiman
Minnesota Chromatography Forum, Minneapolis, MN, 2003 - 63. Genomics and Comprehensive Proteomics in a Single Cell: Technology and Applications
David C. Muddiman
Eastern Tennessee Mass Spectrometry Discussion Group, Knoxville, TN, 2003 - 62. Characterization of Transthyretin by LC-ESI-FT-ICR Mass Spectrometry
David C. Muddiman
University of Tennessee at Knoxville, Knoxville, TN, 2003 - 61. Comprehensive Proteomics in a Single Cell
David C. Muddiman
Mayo Clinic Genetics Society, Mayo Clinic, 2003 - 60. Genomic and Proteomic Measurements in a Single Cell
David C. Muddiman
4th North American ICR Conference, San Francisco, CA, 2003 - 59. Comprehensive Proteomics Using 2DLC-ESI-FT-ICR
David C. Muddiman
Seminar at Mayo Clinic Jacksonville, Jacksonville, FL, 2003 - 58. Comprehensive Proteomics in a Single Cell Using HPLC-FT-ICR-MS
David C. Muddiman
Seminar at 3M Corporation, St. Paul, MN, 2003 - 57. DNA Diagnostics by Mass Spectrometry
David C. Muddiman
Molecular Genetics Development Meeting, Mayo Clinic, Rochester, MN, 2003 - 56. Accurate, Sensitive and Quantitative Nucleic Acid Analyses by ESI-FT-ICR Mass Spectrometry
David C. Muddiman
The Cleveland Clinic Educational Foundation, Department of Cell Biology, Visiting Lecture Pro Tempore, Cleveland, OH, 2003 - 55. ESI-FTICR Mass Spectrometry for Genomic and Proteomic Research: From Fundamentals to Clinically Important Applications
David C. Muddiman
Seminar at the University of California-Riverside, Riverside, CA, 2003 - 54. Genetic Analysis by ESI-FTICR Mass Spectrometry
David C. Muddiman
Lab Automation 2003, Palm Spring, CA, 2003
- 77. MS-Based Proteomics: Instrumentation and Clinical Applications
-
-
-
2002 • Back to top
-
-
-
-
- 53. Genomic and Proteomic Characterization by ESI-FT-ICR Mass Spectrometry using IRMPD
David C. Muddiman
Seminar at the University of Minnesota, Minneapolis, MN, 2002 - 52. ESI-FTICR Mass Spectrometry: From Genotyping to Phosphopeptide Mapping All in a Single Cell
David C. Muddiman
Seminar at the University of Wisconsin at Madison, Madison, WI, 2002 - 51. Determining Allele Frequency for Single-Nucleotide Polymorphisms by Electrospray Ionization FTICR Mass Spectrometry
David C. Muddiman
Desorption 2002, Estes Park, CO, 2002 - 50. From SIMS, ESCA and TOF-SIMS to Biological Chemistry: My Herculoid Experience
David C. Muddiman
Hercules’ Symposium Honoring his 70th Birthday, Nashville, TN, 2002 - 49. Characterization of Biological Molecules by Electrospray Ionization FT-ICR Mass Spectrometry
David C. Muddiman
Mayo-Karolinska Metabolic & Nutrition Conference, Stockholm, Sweden, 2002 - 48. Accurate, Sensitive and Comprehensive Characterization of Biological Molecules by ESI-FT-ICR Mass Spectrometry
David C. Muddiman
Delaware Valley Mass Spectrometry Discussion Group, Merck, West Point, PA, 2002 - 47. Mass Spectrometry and Proteomics: Inseparable Partners
David C. Muddiman
Gannon University and Hamot Medical Center, Erie, PA, 2002 - 46. High Performance Mass Spectrometry for the Study of Biological Complexity
David C. Muddiman
National Research Council of Canada, Halifax, Nova Scotia 2002 – A Canadian Invention for Canadian Research? (aka “The Great Halifax FTICR Caper”) - 45. Extensive Evaluation of Novel Sample Preparation Techniques For Using High Sensitivity Mass Measurements of Nucleic Acids Using ESI-FT-ICR Mass Spectrometry
Laura T. George (2001-2002 Ingraham Scholar) and David C. Muddiman
Richmond Chromatography Discussion Group, Richmond, VA, 2002 - 44. Genomics and Proteomics to Gas-Phase Ion Chemistry: Potential Roles of FTICR Mass Spectrometry in the Post-Genome Era
David C. Muddiman
Mayo Clinic and Foundation, Rochester, MN, 2002 - 43. Accurate Mass Tag – Isotope Coded Affinity Tag LC-ESI-FTICR-MS for Protein Identification and Quantification
David C. Muddiman
American Association of Pharmaceutical Scientists, Toronto, CA, 2002 - 42. High Sensitivity and Mass Accuracy of Large Nucleic Acids
David C. Muddiman
Federation of Analytical Chemistry and Spectroscopy Societies, Providence, RI, 2002 - 41. Genomics to Proteomics: Bridging the Transcriptome with Electrospray Ionization FTICR Mass Spectrometry
David C. Muddiman
Department of Chemistry, University of Pittsburgh, Pittsburgh, PA, 2002 - 40. Novel, Sensitive and Rapid Approaches for Phosphopeptide Mapping
David C. Muddiman
Department of Physiology, Medical College of Virginia, Richmond, VA, 2002 - 39. Mass Spectrometric Approaches to Investigate Biological Systems
David C. Muddiman
Molecular Biology of Cell Growth Meeting, Massey Cancer Center, Medical College of Virginia, Richmond, VA, 2002 - 38. Electrospray Ionization FTICR Mass Spectrometry: A Powerful Platform for a Diverse Range of Post-Genome Applications
David C. Muddiman
Department of Pharmacology and Toxicology, University of Alabama, Birmingham, AL, 2002 - 37. ‘High Throughput’ Genotyping of Length Polymorphisms by Mass Spectrometry: Forensic and Clinical Applications
David C. Muddiman
Lab Automation 2002, Palm Springs, CA, 2002
- 53. Genomic and Proteomic Characterization by ESI-FT-ICR Mass Spectrometry using IRMPD
-
-
-
2001 • Back to top
-
-
-
-
- 36. ESI-FTICR Mass Spectrometry for Genomics and Proteomics Research: From Accurate Mass Determinations for Allele Subtyping to IRMPD for Phosphopeptide Mapping
David C. Muddiman
Pfizer Global, Ann Arbor, MI, 2001 - 35. Nucleic Acid Analysis by High Performance Mass Spectrometry
David C. Muddiman
Washington-Baltimore Mass Spectrometry Discussion Group, Gaithersburg, MD, 2001 - 34. Electrospray Ionization Fourier Transform Ion Cyclotron Resonance Mass Spectrometry of Macromolecules: Putting a Positive Spin on Negative Ions
David C. Muddiman
South Eastern Regional Meeting of the American Chemical Society, Savannah, GA, 2001 - 33. Mass Spectrometric Approaches to Stratify Cancer Using Molecular Signatures
David C. Muddiman
Vanderbilt University, Nashville, TN, 2001 - 32. Mass Spectrometry for the Study of Biocomplexity
David C. Muddiman
Virginia Commonwealth University Life Sciences Scholars’ Program, Richmond, VA, 2001 - 31. Characterization of Macromolecules by Negative Electrospray Ionization Fourier Transform Ion Cyclotron Resonance Mass Spectrometry
David C. Muddiman
Eli Lilly, Indianapolis, IN, 2001 - 30. Electrospray Ionization Fourier Transform Ion Cyclotron Resonance Mass Spectrometry for the Analysis of Large Biomolecules: Instrumentation and Applications
David C. Muddiman
Richmond Chromatography Discussion Group, Whitehall-Robbins, 2001 - 29. Genotyping Short Tandem Repeat Polymorphisms by ESI FT-ICR Mass Spectrometry
David C. Muddiman
Joint Seminar: Departments of Pharmaceutics and Medicinal Chemistry, Medical College of Virginia, 2001 - 28. Electrospray Ionization Fourier Transform Ion Cyclotron Resonance Mass Spectrometry with a DNA Twist
David C. Muddiman
3rd North American FT-ICR MS Conference, Austin, TX, 2001 - 27. Genotyping Short Tandem Repeat Loci Using Accurate Mass Measurements and MS/MS by Electrospray Ionization FT-ICR Mass Spectrometry
David C. Muddiman
Clemson University, Clemson, South Carolina, 2001 - 26. Genotyping Repetitive DNA Sequences with Non-consensus Alleles and Hypervariablity by Electrospray Ionization FT-ICR Mass Spectrometry
David C. Muddiman
Case Western Reserve University, Cleveland, Ohio, 2001 - 25. Genomics to Proteomics: Bridging the Transcriptome with Electrospray Ionization FTICR Mass Spectrometry
David C. Muddiman
Pharmaceutical Congress of the Americas, American Association of Pharmaceutical Scientists, Orlando, FL, 2001
- 36. ESI-FTICR Mass Spectrometry for Genomics and Proteomics Research: From Accurate Mass Determinations for Allele Subtyping to IRMPD for Phosphopeptide Mapping
-
-
-
2000 • Back to top
-
-
-
-
- 24. Electrospray Ionization FT-ICR Mass Spectrometry of Large Biomolecules: Implications of Multiple-Charging for Exact and High Mass Measurements
David C. Muddiman
Workshop on Biological Fourier Transform Ion Cyclotron Resonance Mass Spectrometry, Providence, RI, November 6-7, 2000 - 23. A Novel Algorithm for LC-MS: Enhancements in Both the Signal-to-Noise Ratio and the Resolution of the Analyte Peaks in the Chromatogram
David C. Muddiman
Chromfare, Richmond, VA, 2000 - 22. Genotyping of Simple and Complex Short Tandem Repeats by Electrospray Ionization Tandem Mass Spectrometry
David C. Muddiman
Department of Biology, Virginia Commonwealth University, Richmond, VA, 2000
- 24. Electrospray Ionization FT-ICR Mass Spectrometry of Large Biomolecules: Implications of Multiple-Charging for Exact and High Mass Measurements
-
-
-
1999 • Back to top
-
-
-
-
- 21. Genomics to Gas-Phase Ion Chemistry: The Role of Mass Spectrometry in the Post-Genome Era
D.C. Muddiman
Department of Chemistry and the National High Magnetic Field Laboratory, Florida State University, Tallahassee, Florida, 1999 - 20. Biological Mass Spectrometry: From Small Drugs to DNA
David C. Muddiman
Department of Chemistry, College of William and Mary, Williamsburg, VA, 1999 - 19. Electrospray Ionization Fourier Transform Ion Cyclotron Resonance Mass Spectrometry: From Subattomoles to Gene Mapping
David C. Muddiman
Department of Chemistry, Kent State University, Kent, OH, 1999 - 18. Electrospray Ionization Mass Spectrometry: A Powerful and Universal Platform for the Analysis of Genetic Variation
David C. Muddiman
Department of Chemistry, Louisiana State University, Baton Rouge, LA, 1999 - 17. Investigations of Drug-DNA Interations and Antisense Therapeutics by Electrospray Ionization Fourier Transform Ion Cyclotron Resonance Mass Spectrometry
David C. Muddiman
Massey Cancer Center, Medical College of Virginia, Richmond, VA, 1999 - 16. Electrospray Ionization FT-ICR Mass Spectrometry: A Powerful Platform for Genome and Proteome Characterization
David C. Muddiman
Atlanta Area Mass Spectrometry Discussion Group, Complex Carbohydrate Research Center, University of Georgia, Athens, GA, 1999 - 15. Quantification of Relative Protein Ion Currents by Electrospray Ionization Fourier Transform Ion Cyclotron Resonance Mass Spectrometry
David C. Muddiman
Gordon Research Conference on Analytical Chemistry: Microbioanalytical Measurements for the Next Millennium, Henniker, New Hampshire, 1999 - 14. Rapid and Accurate Characterization of STRs, VNTRs, and Drug-DNA Interactions Through the Development of ESI-FTICR Mass Spectrometry
David C. Muddiman
Functional Genomics: Technology Development and Research Applications, The Banbury Center, Cold Harbor Spring Laboratory, New York, 1999 - 13. Biological Mass Spectrometry: Fundamentals and Applications in Biotechnology
David C. Muddiman
Hampton University, Hampton, VA, 1999
- 21. Genomics to Gas-Phase Ion Chemistry: The Role of Mass Spectrometry in the Post-Genome Era
-
-
-
1998 • Back to top
-
-
-
-
- 12. Fourier Transform Ion Cyclotron Resonance Mass Spectrometry with a DNA Twist
David C. Muddiman
Eastern Analytical Symposium, Gold Medal Award Honoring Professor Alan Marshall, 1998 - 11. Unraveling DNA using Electrospray Ionization Mass Spectrometry: A Powerful Platform for Genetic Mutation Screening
David C. Muddiman
Genome Sequencing and Analysis Conference, The Institute for Genomic Research, Miami Beach, Florida, 1998 - 10. Electrospray Ionization Fourier Transform Mass Spectrometry for Genomic Research
David C. Muddiman
Merck and Co., West Point, PA, 1998 - 9. High Performance Large Molecule Mass Spectrometry: Instrumentation and Genomics Applications
David C. Muddiman
Massey Cancer Center, Medical College of Virginia, 1998
- 12. Fourier Transform Ion Cyclotron Resonance Mass Spectrometry with a DNA Twist
-
-
-
1997 • Back to top
-
-
-
-
- 8. Combining New Analytical Developments with Genomics: A Multi-Disciplinary Approach with a World of Opportunity
David C. Muddiman
Department of Human Genetics, Medical College of Virginia, 1997
- 8. Combining New Analytical Developments with Genomics: A Multi-Disciplinary Approach with a World of Opportunity
-
-
-
1996 • Back to top
-
-
-
-
- 7. Electrospray Ionization Mass Spectrometry of Oligonucleotides
David C. Muddiman
Department of Chemistry and Biochemistry, Montana State University, 1996
- 7. Electrospray Ionization Mass Spectrometry of Oligonucleotides
-
-
-
1995 • Back to top
-
-
-
-
- 6. Biological Applications of Mass Spectrometry: I) Investigation of Drugs, Metabolism and Pharmacokinetics II) Sequencing the Human Genome
David C. Muddiman
Odense University, Department of Molecular Biology, Odense, Denmark, 1995 - 5. Investigation of Oligonucleotides by Electrospray Ionization Mass Spectrometry
David C. Muddiman
University of Münster, Institute for Medicinal Physics and Biophysics, Münster, Germany, 1995
- 6. Biological Applications of Mass Spectrometry: I) Investigation of Drugs, Metabolism and Pharmacokinetics II) Sequencing the Human Genome
-
-
-
1994 • Back to top
-
-
-
-
- 4. Application of Data Analysis Techniques to Time-of-Flight Mass Spectral Data to obtain Quantitative Information
David C. Muddiman, A.I. Gusev, A. Proctor, D.M. Hercules
Desorption ‘94, Bend, Oregon, 1994
- 4. Application of Data Analysis Techniques to Time-of-Flight Mass Spectral Data to obtain Quantitative Information
-
-
-
1993 • Back to top
-
-
-
-
- 3. New Approaches Towards Measurement of Drugs and Metabolites in Microquantities by Time-of-Flight Mass Spectrometry
David C. Muddiman, A.I. Gusev, V. Warty, D.M. Hercules
Department of Clinical Chemistry, Children’s Hospital, Pittsburgh, PA, 1993 - 2. Time-of-Flight Secondary Ion Mass Spectrometry: Instrumentation and Applications
David C. Muddiman, A.G. Sharkey, D.M. Hercules
Department of Geology, University of Pittsburgh, Pittsburgh, Pennsylvania, 1993
- 3. New Approaches Towards Measurement of Drugs and Metabolites in Microquantities by Time-of-Flight Mass Spectrometry
-
-
-
1992 • Back to top
-
-
- 1. Development of New Applications for Time-of-Flight Secondary-Ion Mass Spectrometry
David C. Muddiman, D.M. Hercules
Aluminum Corporation of America (ALCOA), Pittsburgh, Pennsylvania, 1992
- 1. Development of New Applications for Time-of-Flight Secondary-Ion Mass Spectrometry
-
-
-
-
-
-
-
-
-
-
-
-
- 287. Prototyping Mass Spectrometry Imaging Instrumentation
-
- 288. Processing MassTech AP/MALDI Data Using MSiReader v2.8
-